在線訂購 免費訂購熱線:021-59541103 021-60443211
聯(lián)系人:高小姐
電話:021-59541103 021-60443211
手機:13585831301
Q Q: 3004967995
Email:3004967995@qq.com
詳細地址:上海嘉定區(qū)嘉羅公路1661
化學性質:
規(guī)格 | 10mM*1mLinDMSO 5mg 10mg 25mg 50mg 100mg |
CAS | 2097002-61-2 |
別名 | N/A |
化學名 | N/A |
分子式 | C20H21FN6O |
分子量 | 380.42 |
溶解度 | DMSO : 62.5 mg/mL (164.29 mM) |
儲存條件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice |
產品描述:
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor (TKI), with IC50s of 0.6 nM, <2.5 nM for TRKA and TRKC respectively.
Selitrectinib (LOXO-195) demonstrates strong binding to the wild-type TRKA, TRKB and TRKC kinase domains. Selitrectinib (LOXO-195) has potent (IC50<1 nM) inhibitory activity in kinase enzyme assays. Importantly, Selitrectinib (LOXO-195) achieves low nanomolar inhibitory activity against TRKA G595R, TRKC G623R, and TRKA G667C, with IC50s ranging from 2.0-9.8 nM. 228 individual kinases in vitro are profiled at a Selitrectinib (LOXO-195) concentration of 1 μM, which is ~1667-fold higher than its IC50 for TRKA (0.6 nM). Selitrectinib (LOXO-195) is more than 1000-fold selective for 98% of non-TRK kinases tested. Selitrectinib (LOXO-195) demonstrates potent inhibition of cell proliferation in TRK fusion-containing KM12, CUTO-3, and MO-91 cell lines (IC50≤5 nM)[1].
Stably transfected NIH-3T3 δTRKA and δTRKA-G595R cells are implanted subcutaneously into the flanks of nude mice. Both larotrectinib and Selitrectinib (LOXO-195) are effective at reducing phosphorylated TRKA in tumors driven by δTRKA. In contrast, only Selitrectinib (LOXO-195) strongly suppresses phospho-TRKA in δTRKA-G595R cells in a dose-dependent manner. Selitrectinib (LOXO-195) also causes inhibition of tumor growth relative to vehicle at all doses in four TRKA-dependent tumor models (δTRKA, δTRKA-G595R, δTRKAG667C, and TPM3-NTRK1 fusion-positive KM12 colorectal cancer cells. Larotrectinib inhibits KM12 and NIH 3T3-δTRKA tumors to a similar degree. Group mean body weight loss does not exceed 5% for any agent. Selitrectinib (LOXO-195) displays high selectivity for the TRK proteins[1]
[1]. Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017 Sep;7(9):963-972.
特別提醒:
1. 本產品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療,食品及化妝品等用途。請勿存放于普通住宅區(qū)。
2. 為了您的安全和健康,請穿好實驗服并佩戴一次性手套和口罩操作。
原創(chuàng)作者:上海莼試生物技術有限公司
留言注意事項:
1.遵守中華人民共和國有關法律、法規(guī),尊重網上道德,承擔一切因您的行為而直接或間接引起的法律責任。
2.請您真實的反映產品的情況,不要捏造、誣蔑、造謠。如對產品有任何疑問,也可以留言咨詢。
3.未經本站同意,任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質的信息或類似言論。
您感興趣的產品* | |
您的單位* | |
聯(lián)系人* | |
聯(lián)系電話* | |
詳細地址* | |
常用郵箱* | |
請輸入您對我們的意見或建議* | |
驗證碼* | |
產品訂購說明:
1、報價含普票、運費。
2、常用試劑備貨充足,除對溫度要求極其嚴格的產品當天可發(fā)貨。
3、進口原裝產品要3-6周的貨期,詳細情況請咨詢客服。
4、訂貨時間為工作日每周一至周五16:00之前。
5、如需代為檢測,標本對環(huán)境溫度高,可聯(lián)系客服安排專人取樣(限省內客戶)。
6、代測免收代測費,一周出結果。
7、產品因運輸途中包裝破損請拒絕簽收,做退回。我們將在24小時之內為您補發(fā) 損壞產品。
8、如因單位財務制度原因,可申請先發(fā)貨,報賬后付款(此條款僅限醫(yī)院、學校信譽良好客戶)。
普票匯款信息
賬 戶 名:上海生物
開 戶 行:中國銀行山東省分行營業(yè)部
賬 號:2169 2341 6278